All In Biotech

Drug Trial Radar · NCT01986907

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye

Last checked: Nov 20, 2026Latest source record: Jul 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,049

Actual

Start

Mar 4, 2014

Primary completion

Jun 15, 2016

Study completion Jun 15, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).

Conditions

  • Wet Age Related Macular Degeneration

Interventions

  • ranibizumabDrug

    All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Systemic Drug-related Adverse EventsTime frame: Baseline to Month 12
  2. Number of Eyes With Ocular Drug-related Adverse EventsTime frame: Baseline to Month 12

Locations

101 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Borgomanero, Italy

  • Novartis Investigative Site

    Galliate, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Pozzuoli, Italy

  • Novartis Investigative Site

    Alessandria, AL, Italy

  • Novartis Investigative Site

    Casale Monferrato, AL, Italy

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Acquaviva delle Fonti, BA, Italy

  • Novartis Investigative Site

    Putignano, BA, Italy

  • Novartis Investigative Site

    Terlizzi, BA, Italy

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Belluno, BL, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Desenzano del Garda, BS, Italy

  • Novartis Investigative Site

    Bolzano, BZ, Italy

  • Novartis Investigative Site

    Cagliari, CA, Italy

  • Novartis Investigative Site

    Larino, CB, Italy

  • Novartis Investigative Site

    Caserta, CE, Italy

  • Novartis Investigative Site

    Chieti, CH, Italy

  • Novartis Investigative Site

    Ceva, CN, Italy

  • Novartis Investigative Site

    Cuneo, CN, Italy

  • Novartis Investigative Site

    Como, CO, Italy

  • Novartis Investigative Site

    San Feramo Della Battaglia, CO, Italy

  • Novartis Investigative Site

    Acireale, CT, Italy

  • Novartis Investigative Site

    Catania, CT, Italy

  • Novartis Investigative Site

    Catania, CT, Italy

  • Novartis Investigative Site

    Catanzaro, CZ, Italy

  • Novartis Investigative Site

    Forlì, FC, Italy

  • Novartis Investigative Site

    Cona, FE, Italy

  • Novartis Investigative Site

    Foggia, FG, Italy

  • Novartis Investigative Site

    San Giovanni Rotondo, FG, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Rapallo, GE, Italy

  • Novartis Investigative Site

    Crotone, KR, Italy

  • Novartis Investigative Site

    Tricase, LE, Italy

  • Novartis Investigative Site

    Terracina, LT, Italy

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.